Under the leadership of Mai-Britt Zocca, Ph.D., IO Biotech is advancing novel, immune-modulating cancer therapies targeting IDO (indoleamine 2,3-dioxygenase). Though promising, the target fell out of favor after some high-profile misses – most notably Merck's Phase 3 failure with pembrolizumab in 2018. But Immunome's dual mechanism of action is renewing interest in the target, and Dr. Zocca is gaining confidence as the company's data grows. On this episode of the Business of Biotech, she shares the approach, how it differs from previous attempts, and how her company is working to advance its programs in the wake of IDO's fall from grace.